Clinical utilisation of implantable loop recorders in adults with Fabry disease-a multi-centre snapshot study.

Fabry disease arrhythmia implantable loop recorder stroke sudden death

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2023
Historique:
received: 17 10 2023
accepted: 16 11 2023
medline: 25 12 2023
pubmed: 25 12 2023
entrez: 25 12 2023
Statut: epublish

Résumé

Fabry disease (FD) is an X-linked deficiency of alpha-galactosidase-A, leading to lysosomal storage of sphingolipids in multiple organs. Myocardial accumulation contributes to arrhythmia and sudden death, the most common cause of FD mortality. Therefore, there is a need for risk stratification and prediction to target device therapy. Implantable loop recorders (ILRs) allow for continual rhythm monitoring for up to 3 years. Here, we performed a retrospective study to evaluate current ILR utilisation in FD and quantify the burden of arrhythmia that was detected, which resulted in a modification of therapy. This was a snapshot assessment of 915 patients with FD across three specialist centres in England during the period between 1 January 2000 and 1 September 2022. In total, 22 (2.4%) patients underwent clinically indicated ILR implantation. The mean implantation age was 50 years and 13 (59%) patients were female. Following implantation, nine (41%) patients underwent arrhythmia detection, requiring intervention (six on ILR and three post-ILR battery depletion). Three patients experienced sustained atrial high-rate episodes and were started on anticoagulation. Three had non-sustained tachyarrhythmia and were started on beta blockers. Post-ILR battery depletion, one suffered complete heart block and two had sustained ventricular tachycardia, all requiring device therapy. Those with arrhythmia had a shorter PR interval on electrocardiography. This study demonstrates that ILR implantation in FD uncovers a high burden of arrhythmia. ILRs are likely to be underutilised in this pro-arrhythmic cohort, perhaps restricted to those with advanced FD cardiomyopathy. Following battery depletion in three patients as mentioned above, greater vigilance and arrhythmia surveillance are advised for those experiencing major arrhythmic events post-ILR monitoring. Further work is required to establish who would benefit most from implantation.

Identifiants

pubmed: 38144365
doi: 10.3389/fcvm.2023.1323214
pmc: PMC10739315
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1323214

Informations de copyright

© 2023 Roy, Vijapurapu, Kurdi, Orsborne, Woolfson, Kalla, Jovanovic, Miller, Moon, Hughes, Geberhiwot and Steeds.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Ashwin Roy (A)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
Department of Cardiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Ravi Vijapurapu (R)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
Department of Cardiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Hibba Kurdi (H)

Department of Cardiology, Bart Heart Centre, Barts Health NHS Trust, London, United Kingdom.
Lysosomal Storage Disorder Unit, Royal London NHS Foundation Trust, University College London, London, United Kingdom.

Christopher Orsborne (C)

Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom.
Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Peter Woolfson (P)

Department of Cardiology, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.

Manish Kalla (M)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
Department of Cardiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Ana Jovanovic (A)

Department of Metabolic Medicine, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.

Christopher A Miller (CA)

Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom.
Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

James C Moon (JC)

Department of Cardiology, Bart Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Derralynn A Hughes (DA)

Lysosomal Storage Disorder Unit, Royal London NHS Foundation Trust, University College London, London, United Kingdom.

Tarekegn Geberhiwot (T)

Department of Inherited Metabolic Diseases, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom.

Richard P Steeds (RP)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
Department of Cardiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Classifications MeSH